{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+Lung&page=28", "query": { "condition": "Adenocarcinoma Lung", "page": 28 }, "page_size": 10 }, "pagination": { "page": 28, "page_size": 10, "total_count": 911, "total_pages": 92, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+Lung&page=29&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+Lung&page=27&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T15:49:36.724Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06179160", "title": "A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "INCB161734", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Retifanlimab", "type": "DRUG" }, { "name": "GEMNabP", "type": "DRUG" }, { "name": "mFOLFIRINOX", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "INCA33890", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 710, "start_date": "2024-01-04", "completion_date": "2027-01-01", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-15T15:49:36.724Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Palo Alto, California • Santa Monica, California + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06179160" }, { "nct_id": "NCT06122480", "title": "Surgical Resection of Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma", "Oligometastatic Disease" ], "interventions": [ { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 5, "start_date": "2024-05-21", "completion_date": "2026-04-08", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-10-15T15:49:36.724Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06122480" }, { "nct_id": "NCT07227168", "title": "A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma HNSCC", "Non-Small Cell Lung Cancer NSCLC", "Esophageal Cancer", "Gastric Cancer", "Colorectal Cancer", "Pancreatic Ductal Adenocarcinoma (PDAC)", "Cervical Cancer", "Endometrial Cancer", "Urothelial Cancer" ], "interventions": [ { "name": "STRO-004", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sutro Biopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2025-11-07", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-10-15T15:49:36.724Z", "location_count": 9, "location_summary": "San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 6 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07227168" }, { "nct_id": "NCT06451497", "title": "This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer", "Head and Neck Squamous Cell Carcinoma", "Pancreas Adenocarcinoma", "Biliary Tract Cancer", "Prostate Cancer", "Urothelial Carcinoma", "Colorectal Cancer", "Triple Negative Breast Cancer", "High Grade Ovarian Serous Adenocarcinoma", "Diffuse Large B Cell Lymphoma", "Renal Cell Cancer Metastatic" ], "interventions": [ { "name": "ZM008", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Zumutor Biologics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2024-05-22", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-10-15T15:49:36.724Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Austin, TX 78758, Texas • San Antonio, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Austin, TX 78758", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06451497" }, { "nct_id": "NCT00068497", "title": "Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anaplastic Thyroid Cancer", "Insular Thyroid Cancer", "Metastatic Parathyroid Cancer", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Basal Cell Carcinoma of the Lip", "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Lymphoepithelioma of the Nasopharynx", "Recurrent Lymphoepithelioma of the Oropharynx", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Non-small Cell Lung Cancer", "Recurrent Parathyroid Cancer", "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Thyroid Cancer", "Recurrent Verrucous Carcinoma of the Larynx", "Stage III Follicular Thyroid Cancer", "Stage III Papillary Thyroid Cancer", "Stage III Salivary Gland Cancer", "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Verrucous Carcinoma of the Larynx", "Stage IIIB Non-small Cell Lung Cancer", "Stage IV Lymphoepithelioma of the Nasopharynx", "Stage IV Non-small Cell Lung Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IVA Basal Cell Carcinoma of the Lip", "Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IVA Follicular Thyroid Cancer", "Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IVA Lymphoepithelioma of the Oropharynx", "Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IVA Papillary Thyroid Cancer", "Stage IVA Salivary Gland Cancer", "Stage IVA Squamous Cell Carcinoma of the Larynx", "Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVA Squamous Cell Carcinoma of the Oropharynx", "Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVA Verrucous Carcinoma of the Larynx", "Stage IVA Verrucous Carcinoma of the Oral Cavity", "Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IVB Basal Cell Carcinoma of the Lip", "Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IVB Follicular Thyroid Cancer", "Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IVB Lymphoepithelioma of the Oropharynx", "Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IVB Papillary Thyroid Cancer", "Stage IVB Salivary Gland Cancer", "Stage IVB Squamous Cell Carcinoma of the Larynx", "Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVB Squamous Cell Carcinoma of the Oropharynx", "Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVB Verrucous Carcinoma of the Larynx", "Stage IVB Verrucous Carcinoma of the Oral Cavity", "Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IVC Basal Cell Carcinoma of the Lip", "Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IVC Follicular Thyroid Cancer", "Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IVC Lymphoepithelioma of the Oropharynx", "Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IVC Papillary Thyroid Cancer", "Stage IVC Salivary Gland Cancer", "Stage IVC Squamous Cell Carcinoma of the Larynx", "Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVC Squamous Cell Carcinoma of the Oropharynx", "Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVC Verrucous Carcinoma of the Larynx", "Stage IVC Verrucous Carcinoma of the Oral Cavity", "Thryoid Gland Nonmedullary Carcinoma", "Thyroid Gland Medullary Carcinoma", "Tongue Cancer", "Untreated Metastatic Squamous Neck Cancer With Occult Primary" ], "interventions": [ { "name": "gefitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 40, "start_date": "2003-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-14", "last_synced_at": "2026-10-15T15:49:36.724Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00068497" }, { "nct_id": "NCT01414595", "title": "Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "DNA analysis", "type": "GENETIC" }, { "name": "DNA methylation analysis", "type": "GENETIC" }, { "name": "RNA analysis", "type": "GENETIC" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "polymorphism analysis", "type": "GENETIC" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "medical chart review", "type": "OTHER" } ], "intervention_types": [ "GENETIC", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 248, "start_date": "2012-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2017-06-27", "last_synced_at": "2026-10-15T15:49:36.724Z", "location_count": 11, "location_summary": "Los Angeles, California • Lewes, Delaware • Newark, Delaware + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Lewes", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Elkton", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01414595" }, { "nct_id": "NCT02646748", "title": "Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer (CRC)", "Endometrial Cancer", "Melanoma", "Head and Neck Cancer", "Lung Cancer", "MMR-deficient Tumors", "Breast Cancer", "Pancreatic Cancer", "Renal Cell Carcinoma (RCC)", "Solid Tumors", "UC (Urothelial Cancer)" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "itacitinib", "type": "DRUG" }, { "name": "INCB050465", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 159, "start_date": "2016-01-25", "completion_date": "2020-11-20", "has_results": false, "last_update_posted_date": "2022-03-31", "last_synced_at": "2026-10-15T15:49:36.724Z", "location_count": 17, "location_summary": "San Francisco, California • Santa Monica, California • Washington D.C., District of Columbia + 12 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02646748" }, { "nct_id": "NCT02988960", "title": "A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors Cancer" ], "interventions": [ { "name": "ABBV-927", "type": "DRUG" }, { "name": "ABBV-181", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 163, "start_date": "2017-02-22", "completion_date": "2026-09", "has_results": false, "last_update_posted_date": "2026-01-09", "last_synced_at": "2026-10-15T15:49:36.724Z", "location_count": 7, "location_summary": "Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02988960" }, { "nct_id": "NCT06953089", "title": "DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "DB-1311/BNT324", "type": "DRUG" }, { "name": "BNT327", "type": "DRUG" }, { "name": "DB-1305/BNT325", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "DualityBio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 450, "start_date": "2025-07-18", "completion_date": "2030-06-30", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-15T15:49:36.724Z", "location_count": 15, "location_summary": "Los Angeles, California • Wheat Ridge, Colorado • Florida City, Florida + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Wheat Ridge", "state": "Colorado" }, { "city": "Florida City", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06953089" }, { "nct_id": "NCT00041808", "title": "Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastases, Neoplasm", "Colorectal Neoplasms", "Esophageal Neoplasms", "Stomach Neoplasms", "Pancreatic Neoplasms", "Breast Neoplasms", "Melanoma", "Sarcoma", "Gastrointestinal Neoplasms", "Lung Neoplasms", "Liver Neoplasms", "Cholangiocarcinoma" ], "interventions": [ { "name": "MTC-DOX for Injection", "type": "DRUG" }, { "name": "Chemotherapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "FeRx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 20, "start_date": "2001-07", "completion_date": "2003-04", "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-15T15:49:36.724Z", "location_count": 3, "location_summary": "San Diego, California • San Francisco, California • Temple, Texas", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Temple", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00041808" } ] }